Inhibrx Biosciences says ozekibart combination achieves 62.7% ORR in relapsed/refractory Ewing sarcoma
INBX•Inhibrx Biosciences said its ozekibart combination achieved a 62.7% overall response rate and an 86.3% disease control rate, with durable responses, in relapsed/refractory Ewing sarcoma.




